Abstract
Salmonella is responsible for a wide range of infections and is a constant threat to public health, particularly in light of emerging antibiotic resistance. The use of bacteriophages and phage endolysins as specific antibacterial agents is a promising strategy to control this bacterial infection. Endolysins are important proteins during the process of bacteria lysis by bacteriophages. In this study, we identify a novel endolysin, named LysSE24. LysSE24 was predicted to possess N-acetylmuramidases activity, with a molecular mass of ca. 17.4 kDa and pI 9.44. His-tagged LysSE24 was heterologously expressed and purified by Ni-NTA chromatography. LysSE24 exhibited optimal bactericidal activity against Salmonella Enteritidis ATCC 13076 at a concentration of 0.1 μM. Salmonella population (measured by OD600 nm) decreased significantly (p < 0.05) after 10 min of incubation in combination with the outer membrane permeabilizer in vitro. It also showed antibacterial activity against a panel of 23 tested multidrug-resistant Salmonella strains. Bactericidal activity of LysSE24 was evaluated in terms of pH, temperature, and ionic strength. It was very stable with different pH (4.0 to 10.0) at different temperatures (20 to 60 °C). Both K+ and Na+ at concentrations between 0.1 to 100 mM showed no effects on its bactericidal activity, while a high concentration of Ca2+ and Mg2+ showed efficacy. Transmission electron microscopy revealed that exposure to 0.1 μM LysSE24 for up to 5 min caused a remarkable modification of the cell shape of Salmonella Enteritidis ATCC 13076. These results indicate that recombinant LysSE24 represents a promising antimicrobial activity against Salmonella, especially several multidrug-resistant Salmonella strains. Further studies can be developed to improve its bactericidal activity without the need for pretreatment with outer membrane-destabilizing agents by synthetic biology methods.
Keywords: endolysins, bacteriophages, Salmonella, purification, antimicrobial activity
1. Introduction
Salmonella bacteria is the etiologic agent of salmonellosis for humans in many countries for at least over 100 years [1]. Salmonellosis symptoms include nausea, vomiting, abdominal pain, diarrhea, fever, and headache. Salmonella infection can be detected in various foods, including, but not limited to, eggs and egg products, meats, dairy products, fresh fruits, and vegetables [2]. It accounts for 93.8 million cases of foodborne illness and 155,000 deaths in industrialized and underdeveloped countries per year [3]. In the US, it is estimated that salmonellosis cause 1.2 million people with 23,000 hospitalizations and 450 deaths annually [4]. In China, approximately 70 cases of salmonellosis were reported from 2008 to 2012, which led to 4151 hospitalized cases and four deaths in many provinces [5,6,7]. To date, more than 2600 Salmonella serovars have been reported. Of these, the most common serotypes associated with human illness are Salmonella enterica serovar Typhimurium (S. Typhimurium) and S. enterica serovar Enteritidis (S. Enteritidis) [2,8,9,10]. The routine use of antimicrobial agents has been considered as the most effective intervention strategy to eliminate Salmonella contamination. However, the recent rise of multidrug-resistant Salmonella strains leads to a more serious threat to public health, and thus makes developing novel antibiotic alternatives imperative.
Bacteriophages are viruses that infect bacteria. They have been optimized by millions of years of evolution to specifically recognize and effectively kill their target cells [11]. In recent years, the use of lytic bacteriophages has become an option in treating emerging Salmonella serotypes or antimicrobial-resistant Salmonella. The use of phages as biocontrol agents provides several advantages over traditional antibiotic treatment, such as its target specificity without damage to coexisting microflora, inherent low toxicity, robustness to harsh environments, widespread distribution, self-replication, and cheap preparation [12,13]. In addition, bacteriophage endolysins with host specificity and host lysis activities might be preferred to food applications rather than phages [14].
Endolysins (lysins) are bacteriophage-encoded enzymes that degrade specific bonds within the bacterial cell wall, resulting in the release of progeny virions [15,16]. Endolysins are peptidoglycan hydrolases (PGH) and typically differ between Gram-positive and Gram-negative bacteria due to differences in the bacterial cell wall structure. Generally, endolysins targeting Gram-positive bacteria often have a modular structure that includes two conserved protein domains, the N-terminal enzymatic activity domain (EAD) and the C-terminal cell wall binding domain (CBD). Five types of EADs have been reported according to the cleavage sites: N-aceytlmuramidases (endolysins), N-acetyl-b-d-glucosaminidases (glycosidases), N-acetylmuramoyl-l-alanineamidases, l-alanoyl-d-glutamate endopeptidases, and interpeptide bridge-specific endopeptidases [14,17]. Meanwhile, endolysins targeting Gram-negative bacteria exhibit a globular structure that contains a single catalytic domain [18].
Endolysins can be a novel biocontrol agent to kill target bacteria when it is applied exogenously in the form of recombinant proteins. This feature has led to a renewed interest, particularly in light of emerging and spreading resistance of bacteria against classical antibiotics [19]. In the last two decades, endolysins have proven their efficacy in controlling bacterial contamination in food [20] and combating bacterial infection in the fields of medicine [21,22]. Thus, endolysins have increased potential as effective antibacterial agents against infectious pathogens. Endolysins have multiple advantages over antibiotics. First, endolysins specifically target the peptidoglycan layer in the bacteria. So far, no emergences of resistance have been reported to date [23]. Furthermore, endolysins can be modified by genetic engineering to alter their host range and efficiency [24,25]. Finally, endolysins can be cloned into expression vectors for large scale synthesis due to their proteinaceous nature [26]. Endolysins from bacteriophages infecting Gram-positive bacteria have been well studied, but the application of endolysins derived from bacteriophages infecting Gram-negative bacteria is still at the preliminary stage. The outer membrane of Gram-negative bacteria prevents the access of endolysins to the peptidoglycan layer from outside [27,28]. However, the study of OM permeabilizers (OMPs) has aroused hope; OMPs and phage endolysins can be used to work together on Gram-negative bacteria, such as Pseudomonas, E. coli, and Salmonella [19]. To utilize this advantage of endolysins, further efforts and studies need to be conducted on the development of novel phage-based biocontrol agents against foodborne pathogens. Previously, Salmonella Enteritidis targeting bacteriophage LPSE1 was isolated from environmental water. Its genome was completely sequenced [29]. It has a circular genome consisting of 41,854 bp with a GC content of 49.83% and 32 ORFs (open reading frames). In addition, LPSE1, belonging to the Siphoviridae family, infects a broad range of Salmonella strains. In this study, an endolysin LysSE24 from the bacteriophage LPSE1 is purified, and its lysis activity is evaluated.
2. Materials and Methods
2.1. Bacterial Strains, Plasmid and Growth Conditions
The bacterial strains used in this study are described in Table 1. These include a broad range of reference strains as well as multidrug-resistant strains. All strains were stored frozen at −80 °C in 20% (vol/vol) glycerol and cultured in LB medium at 37 °C. Vector pET-28b, E. coli BL21, and E. coli C41 were prepared for cloning and protein expression (Novagen, USA). TSB-YE and LB medium were purchased from Hopebio (Qingdao, China). The protein markers were purchased from SMOBIO (Hsinchu City, Taiwan).
Table 1.
Number | Strain | Strain Type | Source | Drug-Resistance | |
---|---|---|---|---|---|
1 | 13076 | Salmonella Enteritidis | ATCC a | - | |
2 | 38 | Salmonella Enteritidis | Lab Collection | + | Amoxycillin, Ampicillin, Nalidixic acid, Sulfonamides |
3 | 39 | Salmonella Enteritidis | Lab Collection | + | Amoxycillin, Ampicillin, Nalidixic acid |
4 | 42 | Salmonella Enteritidis | Lab Collection | + | Nalidixic acid |
5 | 11561 | Salmonella Enteritidis | Lab Collection | + | Ampicillin, Ceftriaxone, Streptomycin, Nalidixic acid, Trimethoprim-sulfamethoxazole, Azithromycin, Fosfomycin |
6 | 201 | Salmonella Enteritidis | Lab Collection | + | Ampicillin, Amoxycillin/clavulanic acid, Gentamicin, Spectinomycin, Tetracycline, Sulphafurazole, Apramycin |
7 | 211 | Salmonella Enteritidis | Lab Collection | + | Enrofloxacin, Ofloxacin, Apramycin, Colistin |
8 | 10960 | Salmonella Enteritidis | Lab Collection | + | Tetracycline, Nalidixic acid, Fosfomycin |
9 | 14028 | Salmonella Typhimurium | ATCC | - | |
10 | ST-8 | Salmonella Typhimurium | Lab Collection | - | |
11 | 30 | Salmonella Typhimurium | Lab Collection | + | Amoxycillin, Ampicillin, Chloramphenicol, Nalidixic acid, Gentamicin, Nitrofurantoin, Sulfonanides, Tetracycline |
12 | 36 | Salmonella Typhimurium | Lab Collection | + | Amoxycillin, Ampicillin, Chloramphenicol, Straptomycin, Sulfonanides, Tetracycline |
13 | 13336 | Salmonella Typhimurium | Lab Collection | + | Ampicillin, Straptomycin, Gentamicin, Kanamycin, Chloramphenicol, Nalidixic acid, Ofloxacin, Ciprofloxacin, Sulphafurazole, Trimethoprim- Sulfamethoxazole, |
14 | 13350 | Salmonella Typhimurium | Lab Collection | + | Ampicillin, Streptomycin, Gentamicin, Kanamycin, Chloramphenicol, Tetracycline, Nalidixic acid, Ofloxacin, Ciprofloxacin, Sulphafurazole, Trimethoprim-sulfamethoxazole, |
15 | 13277 | Salmonella Typhimurium | Lab Collection | + | Ampicillin, Streptomycin, Gentamicin, Kanamycin, Chloramphenicol, Tetracycline, Nalidixic acid, Ofloxacin, Ciprofloxacin, Sulphafurazole, Trimethoprim-sulfamethoxazole, |
16 | 13337 | Salmonella Typhimurium | Lab Collection | + | Ampicillin Streptomycin, Gentamicin, Kanamycin, Chloramphenicol, Tetracycline, Nalidixic acid, Ofloxacin, Ciprofloxacin, Sulphafurazole, Trimethoprim-sulfamethoxazole, |
17 | 13306 | Salmonella Typhimurium | Lab Collection | + | Ampicillin, Streptomycin, Gentamicin, Kanamycin, Chloramphenicol, Tetracycline, Nalidixic acid, Ofloxacin, Ciprofloxacin, Sulphafurazole, Trimethoprim-sulfamethoxazole, |
18 | 10855 | Salmonella Typhimurium | Lab Collection | + | Ampicillin, Ceftriaxone, Ceftiofur, Kanamycin, Streptomycin, Tetracycline, Doxycycline, Ofloxacin, Sulphafurazole |
19 | UK-1 | Salmonella Typhimurium | Lab Collection | - | |
20 | 114 | Salmonella Typhimurium | Lab Collection | + | Ampicillin, Amoxycillin/Clavulanic acid, Gentamicin, Spectinomycin, Tetracycline, Sulphafurazole, Trimethoprim-sulfamethoxazole, Apramycin, Colistin, Mequindox |
21 | 172 | Salmonella Typhimurium | Lab Collection | + | Amoxycillin/Clavulanic acid, Florfenicol, Sulphafurazole, Trimethoprim-sulfamethoxazole, Ceftiofur, Ceftazidime, Meropenem, Apramycin |
22 | 206 | Salmonella Typhimurium | Lab Collection | + | Sulphafurazole, Trimethoprim-sulfamethoxazole, Colistin, Mequindox |
23 | 17 | Salmonella Argora | Lab Collection | + | Amoxycillin, Ampicillin, Streptomycin, Sulfonamides, Tetracycline |
24 | 19 | Salmonella Argora | Lab Collection | + | Amoxycillin, Ampicillin, Cephazolin, Nalidixic acid |
25 | 21 | Salmonella Argora | Lab Collection | + | Chloramphenicol |
26 | 13500 | Salmonella Indiana | Lab Collection | + | Ampicillin, Amoxycillin/Clavulanic Acid, Streptomycin, Tetracycline, Ceftriaxone, Trimethoprim-sulfamethoxazole, Nalidixic acid, Ciprofloxacin, Fosfomycin, Chloramphenicol, Azithromycin |
27 | 13520 | Salmonella Indiana | Lab Collection | + | Ampicillin, Amoxycillin/clavulanic acid, Amikacin, Streptomycin, Tetracycline, Ceftriaxone, Trimethoprim-sulfamethoxazole, Nalidixic acid, Ciprofloxacin, Fosfomycin, Chloramphenicol, Azithromycin |
28 | 9270 | Salmonella Anatum | CMCC b | - | |
29 | 3723 | Salmonella Dublin | Lab Collection | - | |
30 | DH5α | Escherichia coli | Lab Collection | - | |
31 | T10 | Escherichia coli | Lab Collection | - | |
32 | F18ac | Escherichia coli | Lab Collection | - | |
33 | 6538 | Staphylococcus aureus | Lab Collection | - |
+, Strain was drug-resistant; -, strain was not drug-resistant. a ATCC, American Type Culture Collection. b CMCC, Center for Medical Culture Collections.
2.2. Bioinformatics Analysis of LysSE24
From the complete genome sequence of Salmonella phage LPSE1 (NCBI accession no. KY379853.1), the possible DNA sequence encoding endolysin LysSE24 (NCBI accession number: APU02985.1) was identified. The physical and chemical properties of the LysSE24 sequence, including molecular weight, isoelectric point, instability coefficient, and hydrophilic coefficient, were predicted by the online tool ProtParam https://web.expasy.org/protparam/). BLASTP was used to search the non-redundant database to find the amino acid sequence similar to LysSE24. At the same time, the sequences of Salmonella phage endolysins (from BLASTP) were compared by Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/) and software Jalview 2.11.0. Then, the conserved domain was predicted by NCBI Conserved Domain Database and Pfam database. The secondary structure of the LysSE24 sequence was predicted by the online tool JPred online server in the software Jalview 2.11.0. The tertiary structure analysis was carried out using the Swiss-Model online server ( http://swissmodel.expasy.org). The evaluation of the tertiary structure model refers to the Ramachandran Plot by using software BIOVIA Discovery Studio 2019, and Verify-3D evaluation was carried out by using The Structure Analysis and Verification Server version 5.0 (https://servicesn.mbi.ucla.edu/Verify3D/). The tertiary structure of LysSE24 was visualized by software VMD 1.9.1.
2.3. Cloning, Expression, and Purification of LysSE24
The gene encoding LysSE24 was amplified by PCR using DNA of phage LPSE1 as the template. It is with a His-tag at the C-terminal. The primers were designed as forward primer: 5′-CCATATGATGTCAAACCGAAACATCAGTG-3′, reverse primer: 5′-CCTCGAGGCTACTTCGCATCGCGCCCTAC-3′, with the NdeI/XhoI restriction endonuclease sites underlined. Next, the PCR product was digested with NdeI and XhoI and then ligated into the NdeI- and XhoI-linearized vector pET-28b to construct recombinant plasmids for endolysin LysSE24 expression.
In order to optimize the expression of endolysin, it was detected in different expression strains and different temperatures. Firstly, the recombinant plasmid was transformed into E. coli BL21 and E. coli C41, respectively. A single colony of each transformant was cultured overnight in 5 mL LB medium supplemented with 50 μg/mL kanamycin (LBK) at 37 °C. After overnight, the culture was used to inoculate another 5 mL of fresh LBK, and 100 mL batch of LBK was inoculated when the OD600 nm value was close to 0.6. When the culture of OD600 nm was approximately 1.0, the expression of endolysin can be initiated by adding IPTG to a final concentration of 0.25 mmoL/L. Induction was conducted and attempted for 16 h with shaking at 16 °C, 4 h with shaking at 30 °C, and 4 h with shaking at 37 °C, respectively. The culture was collected by centrifugation at 7000× g for 20 min. The supernatant was washed three times with phosphate-buffered saline (PBS; 50 mmol/L NaH2PO4, 300 mmol/L NaCl, pH 7.5). Finally, the particles were resuspended in 40 mL PBS and ultrasonic crushed at a temperature below 10 °C (30 min 2 s on, 2 s 105 W off) using an ice bath. The supernatant (the native protein extract after sonication, NPE) and the denatured protein extract (solubilization of the pellet after sonication in 8.0 moL/L urea, DPE) were collected for the SDS-PAGE analysis. The NPE was collected and then purified with HisPur Ni-NTA spin columns according to the manufacturer’s protocol. Protein was quantitated by the Bradford method. Purified protein was exchanged into storage buffer (20 mM PBS, pH 7.5) and stored at −80 °C until use.
2.4. The Lytic Activity Determination of Endolysin LysSE24
The lytic activity of endolysin LysSE24 was quantitatively assayed using improved Mikoulinskaia turbidity method with slight modification [30]. Salmonella Enteritidis ATCC13076 was inoculated in TSB-YE medium, and cultured to a logarithmic growth phase. Then, chloroform was added to a final concentration of 0.5% (v/v) and kept for 20 min. The cells were centrifuged (8000 r/min, 20 min). The cultures were repeatedly washed with sterile deionized water, and then the cells were collected by centrifugation. The bacterial pellet was resuspended in 50 mM Tris-HCl buffer containing 0.1% Triton X-100 (pH 8.2), and adjusted to an OD600 nm of 0.8~1.0. A total of 50 μL endolysins LysSE24 in different final concentrations (from 50 μM to 0.01 μM) were added to 200 μL of bacterial resuspension. OD600 nm was monitored every 5 min at room temperature with Swiss Tecan M200 PRO multifunctional enzyme labeling instrument. The maximum decreased concentration of OD600 nm within 40 min was selected as the optimum concentration for the subsequent experiments. The same volume of Tris-HCl buffer with 0.1% Triton X-100 instead of endolysins was used as the negative control. All analyses were performed in triplicate using Salmonella Enteritidis ATCC13076 as target strain. The mean values were calculated unless otherwise stated.
2.5. Biochemical Characterization of Endolysin LysSE24
To investigate the thermal stability of LysSE24, 0.5 μM of each endolysin was incubated at different temperatures (20–90 °C) in a water bath for 30 min followed by a cooling step to room temperature. The lytic activity was then measured by turbidity reduction assay [23].
The influence of pH on the lytic activity of LysSE24 was assessed using chloroform permeabilized cells. These cells were resuspended in a universal pH buffer (20 mmol/L sodium citrate, 20 mmol/L sodium malonate, 20 mmol/L Tris-HCl, and 20 mmol/L glycine), and adjusted to different pH’s between 4.0 and 12.0.
The influences of ionic strength on lysis activity were also determined, respectively. NaCl, KCl, CaCl2, and MgCl2 were prepared at a final concentration of 0.1–10 mmoL/L The chloroform treated bacteria cells were prepared as mentioned earlier. Then, 50 μL 100 nM of treated endolysins were mixed with 200 μL of the bacterial resuspension. The OD600 nm was monitored every 5 min at room temperature. The lytic activity was calculated using the following equation: 100% × (OD600 nm of control − OD600 nm of the reaction mixture with endolysins)/the initial OD600 nm of the control. All the selected calculated data are the OD600 nm values measured for 40 min.
2.6. Antibacterial Activity of LysSE24 in Combination with Outer Membrane Permeabilizers (OMPs)
The antibacterial activity of LysSE24 combined with OMPs was determined as previously reported with slight modifications [31]. Salmonella Enteritidis ATCC13076 was inoculated in TSB-YE liquid medium containing 0.6% yeast extract, and cultured to a logarithmic growth phase. Afterward, chloroform was added to a final concentration of 0.5% (v/v) and kept for 20 min. The bacteria treated with chloroform were centrifuged (8000 r/min, 20 min). The cells were repeatedly washed with sterile deionized water. Prior to assaying the activity, the bacterial pellet was resuspended in 50 mM Tris-HCl buffer (pH 8.2) containing the different OMPs (0.1% Triton X-100, 2 mM citric acid and 0.5 mM EDTA, and adjusted to an OD600 nm of 0.8~1.0). Then, 50 μL endolysin in different final concentrations were added to 200 μL of bacterial resuspension. OD600 nm was monitored every 5 mins at room temperature. The same volume of Tris-HCl buffer containing different OMPs was used instead of the endolysins for control.
2.7. The Lytic Spectrum of LysSE24
For the determination of the antibacterial spectrum of LysSE24, 33 strains were used (Table 1), including 23 strains of drug-resistant Salmonella. The relative lytic activity was measured according to the method described in Section 2.4 and calculated using the equation in Section 2.5.
2.8. Observation by Transmission Electron Microscopic (TEM)
TEM was used to visualize the effect of LysSE24 on bacterial cells. Salmonella Enteritis ATCC13076 was inoculated in TSB-YE liquid medium containing 0.6% yeast extract, and cultured to the logarithmic growth phase. The cells were treated with 0.5 mM EDTA for 20 min. The medium containing EDTA was removed by centrifugation. The cells were washed with sterile water 4 times. Then, 50 mM Tris-HCl buffer containing 0.5 mM EDTA (pH 8.2) was used to adjust the OD600 nm of the bacterial solution to 0.8–1.0. The endolysin LysSE24 was added to a final concentration of 100 nM. For all experiments, 50 mM Tris-HCl of 0.5 mM EDTA (pH8.2) was used as a negative control. After 10 min incubation, cells were fixed with glutaraldehyde at a final concentration of 25% and washed with PBS. Cells were then treated with metaperiodate (1% final concentration, 15 min incubation) and osmium tetroxide plus hexacyanoferrate (1% and 1.5%, respectively; 1 h incubation). Cells were then centrifuged, and the pellets were spun down in microcentrifuge tubes containing melted agar. After solidification of the agar, pellets were embedded in epon for ultra-thin sections (50 nm) preparation, as described. Micrographs were taken with a transmission electron microscope HT7700 (HITACHI, Japan) at an acceleration voltage of 80 kV.
2.9. Statistical Analysis
Statistical analysis of the data was performed using the software OriginPro2018 (OriginLab, Northampton, MA, USA). The data were analyzed using the Statistical Package for Social Sciences (SPSS, Chicago, IL, USA) and differences between means were assessed for statistical differences using the Student–Newman–Keuls test (p < 0.05). The results show a confidence interval of 95% of the mean. The comparison method of the data is the SNK method (also known as Q test, which is suitable for the comprehensive comparison of the mean of multiple samples) to judge whether there is statistical significance at the test level α = 0.05. All experiments were done in triplicate.
3. Results and Discussion
3.1. Bioinformatics Analysis of LysSE24
Salmonella phage LPSE1 was previously isolated and sequenced [29]. Among 32 ORFs, ORF24, referred to as LysSE24, was identified as a putative endolysin. The physicochemical properties of the LysSE24 sequence were analyzed by the ProtParam tool. LysSE24 consists of 162 amino acids with a molecular weight of 17.4 kD and an isoelectric point of 9.44. The instability coefficient is 34.60 and the hydrophilic coefficient is −0.291. Generally speaking, an instability coefficient of less than 40 indicates that the protein is stable. The negative hydrophilic coefficient indicates that the protein has a certain hydrophilicity [32].
Sequence alignment analysis of LysSE24 by BLASTP showed that LysSE24 had high similarity with 29 strains of bacteriophage endolysin. The sequences in the result of BLASTP were selected for multi-sequence alignment, which were Salmonella phage W71701E2 (similarity 98.77%, E-value 2 × 10−113), ST4 (similarity 91.98%, E-value 6 × 10−100), BPS11Q3 (similarity 91.98%, E-value 7 × 10−98), phi68 (similarity 91.36%, E-value 4 × 10−97), and SETP13 (similarity 90.57%, E-value 4 × 10−92) (Figure 1A). The LysSE24 sequence was conserved and had high homology with other Salmonella bacteriophages. Subsequently, the conserved domain of LysSE24 was analyzed by NCBI CDD and Pfam 32.0. According to NCBI CDD prediction, it belonged to the Lyz endolysin autolysin domain family (Accession cd00737), between 10 and 147 aa [33]. Pfam predicts that LysSE24 had a phage lysozyme domain (Accession PF00959.19) from 33 to 141 aa (Figure 1B) [34]. The analysis showed that LysSE24 could hydrolyze the 1,4-β-bond between N-acetyl-d-glucosamine and N-acetylmuramic acid in the peptidoglycan heteropolymer of the prokaryotic cell wall, confirming that it is a lysozyme (N-acetylmuramidases).
JPred in the software Jalview2.11.0 was used to predict the secondary structure of the amino acid sequence of LysSE24. Meanwhile, JPred can also use HMM and PSSM methods to predict the secondary structure of proteins (Figure 1B). The prediction results of LysSE24 by JPred, HMM, and PSSM are consistent. The secondary structure of LysSE24 is mainly helix and less lamellar structure, so it can be inferred that the lyase has a stable structure [35]. The homologous modeling method is used to simulate the three-level structure of LysSE24 in SWISS-Model. In the modeling results, PDB ID 6et6.1.A was selected as the modeling template. Additionally, LysSE24 and 6et6.1.A seq identities were 33.10% and QMEAN-2.14, respectively. The constructed LysSE24 model was highly reliable (Figure 1C) [36]. The quality of the LysSE24 model was evaluated by a Ramachandran plot and Verify-3D. In the Ramachandran plot, the Gly at positions 42 and 48 are in the unreasonable region, the rest of the amino acids are in the most suitable region and allowable region, and 92.59% of the amino acids are in the most suitable region (Figure 1D). In the Verify-3D assessment, at least 80% of the amino acids scored ≥0.2 in the 3D-1D profile, and LysSE24 had 95.95% of the residues with an averaged 3D-1D score ≥0.2, so the model of LysSE24 was passed [37]. In conclusion, the homologous modeling of LysSE24 was credible.
3.2. Large Scale Expression and Purification Endolysin LysSE24
To optimize the expression of LysSE24, different expression parameters were tested. The expression vectors encoding one possible endolysin were constructed and then transformed into E. coli BL21 and E. coli C41, respectively. Both NPE and DPE portion collected after induction were subjected to SDS-PAGE. As shown in Figure 2A, new obvious bands at 17 kDa appeared after induction, respectively, which were consistent with the predicted size of LysSE24 through ExPASy (http://web.expasy.org/compute_pi/). For LysSE24, a larger yield was obtained when E. coli BL21 was induced at 16 °C for 16 h. After large scale-up expression, LysSE24 in supernatant fractions was purified by a Ni-NTA column, and analyzed by SDS-PAGE. Figure 2B indicated that high-purity LysSE24 was obtained. The purity was about 90% by using the Bradford method, which yielded a soluble protein of 175.5 mg per liter of culture.
3.3. The Lytic Activity of the Endolysin LysSE24
The lytic activity of LysSE24 was determined by turbidimetry, as shown in Figure 3. When the final concentration of LysSE24 was from 100 nM to 50 μM for 10 min, the turbidity of Salmonella Enteritis ATCC 13076 decreased significantly. Then, 100 nM LysSE24 was selected to act on Salmonella and OD600nm was determined every 5 min for a total of 60 min. The results showed that when 100 nM LysSE24 acted on Salmonella Enteritis 13076 for 10 min, OD600nm decreased from 1.0 to 0.5 (p < 0.05), which could reach half inhibition. Therefore, LysSE24, with the final concentration of 100 nm, was selected as the protein concentration of the follow-up experiment. This result showed that LysSE24 exhibited relatively high lytic activity on Salmonella [38,39,40].
3.4. Characterization of the Endolysin LysSE24
3.4.1. Temperature Resistance
To test the characteristics of endolysins, the lytic activity of LysSE24 was investigated at various temperatures. As shown in Figure 4, the lytic activity of LysSE24 was approximately 75% when incubated at 20 to 60 °C for 30 min. The activity is reduced significantly (p < 0.05) after 60 °C and reduced slowly at 70 to 90 °C for 30 min. Therefore, LysSE24 is more tolerant of high temperatures than previously reported endolysins, which was similar to endolysins Gp110 and LysPA26. The enzyme was treated at a high temperature for 30 min. The lytic activity was restored after being allowed to stand at room temperature [23,41].
3.4.2. pH Dependence of Endolysin LysSE24 Enzymatic Activity
The dependence of pH on the lytic activity of LySE24 was tested. The endolysin showed high lytic activity at pH 4.0 to 10.0 (Figure 4), which were about 80% and 75%, respectively. When the pH was greater than 10.0, a significant decrease in activity was observed (p < 0.05). Therefore, it was speculated that LysSE24 had higher lytic activity under slightly acidic, neutral, and slightly alkaline conditions, and the cleavage rate was higher at pH 8.0. Precipitation occurred at pH 2.0, demonstrating that endolysin could not tolerate a highly acidic environment. Therefore, it was speculated that LysSE24 was an alkalophilic endolysin. The trends of their activities that were affected by pH were similar to endolysins LysIS 075 and LysCER057 [42] but different from the neutrophilic endolysins from Lys68 [43], which showed optimum activity at 7.5 and 7.0, respectively.
3.4.3. The Different Metal Ionic Effect of LysSE24 Activity
The lytic activity of metal ions on LysSE24 was shown in Figure 5. When potassium ions and sodium ions are at 0.1, 1, and 10 mM, there is no significant inhibitory effect on the cleavage activity of LysSE24 (p > 0.05). At 100 mM, both potassium and sodium ions showed some inhibition, but not strong inhibition (p < 0.05). The inhibitory effect of the calcium and magnesium ions on the lytic activity of LysSE24 was evident at 10 and 100 mM. As the concentration of divalent metal ions increases, the lytic activity of the endolysin LysSE24 decreases, and at 100 mM, the lytic rate is minimized. The results showed that the inhibitory effect of high concentration of univalent metal ion (Na+ and K+) on the lytic activity of internal endolysin LysSE24 was significantly lower than that of high concentration of divalent metal ion (Ca2+ and Mg2+; p < 0.05). When the concentration of these four metal ions was as high as 10 mmol/L, the lytic activity of endolysin LysSE24 decreased significantly, which is consistent with the endolysins produced by bacteriophages λSA2 and B30 [44]. Divalent metal ions bind to amino acid residue sites on different domains of the endolysin, which resulted in a difference in the activity of the endolysins [45,46]. The binding reaction of the metal ions with LysSE24 needs further study.
3.5. Antibacterial Activity of LysSE24 in Combination with OMPs
The thicker outer membrane of Gram-negative bacteria is the main barrier to the lytic function of phage lysins on the peptidoglycan layer. When applied to Gram-negative bacteria alone, endolysins are usually ineffective or inefficient. In the current study, endolysins derived from phage are often combined with an outer membrane permeabilizing agent to enhance antibacterial efficacy. The antibacterial activity of LysSE24 in combination with 0.5 mM EDTA, 2 mM citric acid (CA), or 0.1% (v/v) Triton X-100 was determined.
As shown in Figure 6, the cells were first treated with 0.5% (v/v) chloroform for 5 min; then, the chloroform was washed away. Additionally, the cells were washed three times with sterile deionized water in the blank group (only endolysin LysSE24 was added). In the 0.5 mM EDTA and 2 mM CA group, the lytic activity rate reached more than 70% after the addition of the endolysin LysSE24. The lytic rate was above 75% in the group added with 0.1% Triton X-100 (v/v). After combining endolysin LysSE24 with Triton X-100 or 0.5% (v/v) chloroform, the endolysin LysSE24 showed the strongest antibacterial effect.
Due to the protection of the outer membrane, Gram-negative bacteria have great resistance to exogenous endolysins. Removal of the outer membrane with chloroform could significantly improve the cleavage activity of LysSE24 to host bacteria. Chloroform treatment showed high efficiency in destabilizing the outer membrane and allowed lysine to reach peptidoglycan in turbidity reduction analysis [30,38,39]. In this study, the LysSE24 of 100 nM and the commonly used outer membrane permeating agent reduced the turbidity of chloroform-treated host strains by more than 70% in 10 min, indicating that LysSE24 has rapid and strong lytic activity against Salmonella Enteritidis (p < 0.05). Outer membrane permeating agents such as chloroform cannot dissolve bacterial cells themselves. However, they can be used as triggers to easily permeate the cell membrane and allow endolysin to spread to the periplasm [47]. An example of the combined application of endolysin and OM permeabilizer was provided by Oliveira et al. They demonstrated that the combination of Lys68 of Salmonella bacteriophage with citric acid or malic acid killed Salmonella and other Gram-negative organisms [43]. However, some endolysins of bacteriophage show intrinsic antibacterial activity against Gram-negative bacteria without OMPs, such as endolysin of phage CfP1 against Citrobacter freunii [48]. However, the exact pattern of these endolysins is unclear and deserves further study [27]. In the future, it is possible to develop a biocide combining OMPs with endolysins, and apply this new biocide to agricultural and food safety control to control the contamination of food-borne Gram-negative bacteria, especially Salmonella.
3.6. The Lytic Spectrum of the Endolysin LysSE24
The 33 strains were utilized to determine the lytic spectrum of LysSE24 (Table 1). As shown in Figure 7, LysSE24 was able to lytic all the Gram-negative strains listed, i.e., capable of lysing 32 of them (32/33 = 96.97%). Among them, LysSE24 was able to lytic 23 strains of different Gram-negative bacteria, including Salmonella Typhimurium, Salmonella Enteritidis, Salmonella Argora, Salmonella Indiana, Salmonella Anatum, Salmonella Dublin, and E. coli. They showed a better lytic effect on different serotypes of drug-resistant Salmonella. The endolysin LysSE24 showed no lytic effect on one Gram-positive strain. Similarly, endolysin LysPA26 and LySMP from bacteriophages also showed a broader lytic spectrum than their entire bacteriophages [41,49]. In general, endolysin is genus- or species-specific, that is, endolysin in Salmonella phage may only be active against different serotypes of Salmonella. However, in a few cases, this endolysin may be active against other genera, even against Gram-positive and Gram-negative strains. LysSE24 can lytic Salmonella and E. coli. At present, due to the continuous growth of bacterial drug resistance, there is an urgent need to find substitutes for antibiotics to control pathogenic bacteria. In this study, 100 nM LysSE24 can cleave a panel of 23 tested multidrug-resistant Salmonella strains, and it will have a prospect as a biological agent to control multidrug-resistant bacteria. More importantly, until now, no specific resistance of bacteria to endolysins has been reported [50].
3.7. Observation by Transmission Electron Microscopy (TEM)
The effect of LysSE24 on S. Enteritidis ATCC 13076 structure was visualized by TEM. As shown in Figure 8, exposure to 100 nM of endolysin LysSE24 led to drastic changes in intracellular density and to the disintegration of the cell wall and the cell membrane. As similar as endolysin LytSD and PlyE146, it can be concluded that the strain suffered severe damage after being treated by endolysin LysSE24, which was not only reflected in the cell wall but also on the cell membrane [27,51].
4. Conclusions
In this study, we confirmed the lytic activity of an endolysin homologue from LPSE1, a newly isolated bacteriophage infecting Salmonella Enteritidis. Endolysin LysSE24 has a lysozyme-like superfamily domain and its characterization was verified. Overall, this globular endolysin exhibits a broad and high activity against Gram-negative pathogens, especially several multidrug-resistant Salmonella strains in vitro. Further studies can be developed to improve its bactericidal activity without the need for outer membrane-destabilizing agents by synthetic biology methods.
Author Contributions
Conceptualization, X.W. and J.W.; methodology, X.W., J.W., Y.D., and C.H.; software, Y.D.; investigation, Y.Z.; resources, X.W.; data curation, C.H.; writing—original draft preparation, Y.D.; writing—review and editing, X.W.; supervision, X.W.; project administration, X.W.; funding acquisition, X.W.. All authors have read and agreed to the published version of the manuscript.
Funding
This research was supported by the National Natural Science Foundation of China (31772054) and the National Key R&D Program of China (2019YFC1606000, 2017YFC1600100).
Conflicts of Interest
The authors declare no conflict of interest.
References
- 1.Lee K.-M., Runyon M., Herrman T.J., Phillips R., Hsieh J. Review of Salmonella detection and identification methods: Aspects of rapid emergency response and food safety. Food Control. 2015;47:264–276. doi: 10.1016/j.foodcont.2014.07.011. [DOI] [Google Scholar]
- 2.European Food Safety Authority and European Centre for Disease Prevention and Control (EFSA and ECDC) The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017. EFSA J. 2018;16:5500. doi: 10.2903/j.efsa.2018.5500. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Eng S.-K., Pusparajah P., Ab Mutalib N.-S., Ser H.-L., Chan K.-G., Lee L.-H. Salmonella: A review on pathogenesis, epidemiology and antibiotic resistance. Front. Life Sci. 2015;8:284–293. doi: 10.1080/21553769.2015.1051243. [DOI] [Google Scholar]
- 4.Scallan E., Hoekstra R.M., Angulo F.J., Tauxe R.V., Widdowson M.A., Roy S.L., Jones J.L., Griffin P.M. Foodborne illness acquired in the united states—Major pathogens. Emerg. Infect. Dis. 2011;17:7–15. doi: 10.3201/eid1701.P11101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Ke B., Sun J., He D., Li X., Liang Z., Ke C.-W. Serovar distribution, antimicrobial resistance profiles, and PFGE typing of Salmonella Enterica strains isolated from 2007–2012 in Guangdong, China. BMC Infect. Dis. 2014;14:338. doi: 10.1186/1471-2334-14-338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Luo Q., Li S., Liu S., Tan H. Foodborne illness outbreaks in China, 2000–2014. Int. J. Clin. Exp. Med. 2017;10:5821–5831. [Google Scholar]
- 7.Huang X., Huang Q., Shi W., Liang J.H., Ling-Ling L.U., Deng X.L., Zhang Y.H. Epidemiological burden of nontyphoidal Salmonella infection in Guangzhou. Chin. J. Food Hyg. 2014;26:3. [Google Scholar]
- 8.Haraga A., Ohlson M.B., Miller S.I. Salmonella interplay with host cells. Nat. Rev. Genet. 2008;6:53–66. doi: 10.1038/nrmicro1788. [DOI] [PubMed] [Google Scholar]
- 9.Bula-Rudas F.J., Rathore M., Maraqa N.F. Salmonella Infections in Childhood. Adv. Pediatr. 2015;62:29–58. doi: 10.1016/j.yapd.2015.04.005. [DOI] [PubMed] [Google Scholar]
- 10.CDC . Foodborne Diseases Active Surveillance Network (FoodNet): FoodNet Surveillance Report for 2012 (Final Report) U.S. Department of Health and Human Services, CDC; Atlanta, GA, USA: 2014. [Google Scholar]
- 11.Rohwer F. Global phage diversity. Cell. 2003;113:141. doi: 10.1016/S0092-8674(03)00276-9. [DOI] [PubMed] [Google Scholar]
- 12.Zhang J., Li Z., Cao Z., Wang L., Li X., Li S., Xu Y. Bacteriophages as antimicrobial agents against major pathogens in swine: A review. J. Anim. Sci. Biotechnol. 2015;6:39. doi: 10.1186/s40104-015-0039-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Cerqueira M.A., Oliveira H., Azeredo J. Bacteriophages and Their Role in Food Safety. Int. J. Microbiol. 2012;2012:1–13. doi: 10.1155/2012/863945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Bai J., Kim Y.-T., Ryu S., Lee J.-H. Biocontrol and Rapid Detection of Food-Borne Pathogens Using Bacteriophages and Endolysins. Front. Microbiol. 2016;7:6230. doi: 10.3389/fmicb.2016.00474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Loessner M.J. Bacteriophage endolysins—Current state of research and applications. Curr. Opin. Microbiol. 2005;8:480–487. doi: 10.1016/j.mib.2005.06.002. [DOI] [PubMed] [Google Scholar]
- 16.Fischetti V.A. Bacteriophage lytic enzymes: Novel anti-infectives. Trends Microbiol. 2005;13:491–496. doi: 10.1016/j.tim.2005.08.007. [DOI] [PubMed] [Google Scholar]
- 17.Borysowski J., Weber-Dabrowska B., Górski A. Bacteriophage Endolysins as a Novel Class of Antibacterial Agents. Exp. Boil. Med. 2006;231:366–377. doi: 10.1177/153537020623100402. [DOI] [PubMed] [Google Scholar]
- 18.Pohane A.A., Jain V. Insights into the regulation of bacteriophage endolysin: Multiple means to the same end. Microbiology. 2015;161:2269–2276. doi: 10.1099/mic.0.000190. [DOI] [PubMed] [Google Scholar]
- 19.Schmelcher M., Donovan D.M., Loessner M.J. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012;7:1147–1171. doi: 10.2217/fmb.12.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Schmelcher M., Loessner M.J. Bacteriophage endolysins: Applications for food safety. Curr. Opin. Biotechnol. 2016;37:76–87. doi: 10.1016/j.copbio.2015.10.005. [DOI] [PubMed] [Google Scholar]
- 21.Nelson D., Schmelcher M., Rodriguez-Rubio L., Klumpp J., Pritchard D.G., Dong S., Donovan D.M. Endolysins as Antimicrobials. Adv. Appl. Microbiol. 2012;83:299–365. doi: 10.1016/b978-0-12-394438-2.00007-4. [DOI] [PubMed] [Google Scholar]
- 22.Roach D.R., Donovan D.M. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage. 2015;5:e1062590. doi: 10.1080/21597081.2015.1062590. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Rodriguez-Rubio L., Gerstmans H., Thorpe S., Mesnage S., Lavigne R., Briers Y. DUF3380 Domain from a Salmonella Phage Endolysin Shows Potent N-Acetylmuramidase Activity. Appl. Environ. Microbiol. 2016;82:4975–4981. doi: 10.1128/AEM.00446-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Díez-Martínez R., Fernández H.D.D.P., De Paz H.D., Bustamante N., Euler C.W., Fischetti V.A., Menéndez M., García P. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against Streptococcus pneumoniae. J. Antimicrob. Chemother. 2015;70:1763–1773. doi: 10.1093/jac/dkv038. [DOI] [PubMed] [Google Scholar]
- 25.Blázquez B., Fresco-Taboada A., Iglesias-Bexiga M., Menéndez M., García P. PL3 Amidase, a Tailor-made Lysin Constructed by Domain Shuffling with Potent Killing Activity against Pneumococci and Related Species. Front. Microbiol. 2016;7:2157. doi: 10.3389/fmicb.2016.01156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Fernández-Ruiz I., Coutinho F.H., Rodriguez-Valera F. Thousands of Novel Endolysins Discovered in Uncultured Phage Genomes. Front. Microbiol. 2018;9:1033. doi: 10.3389/fmicb.2018.01033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Larpin Y., Oechslin F., Moreillon P., Resch G., Entenza J.M., Mancini S. In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria. PLoS ONE. 2018;13:e0192507. doi: 10.1371/journal.pone.0192507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Yan G., Liu J., Ma Q., Zhu R., Guo Z., Gao C., Wang S., Yu L., Gu J., Hu D., et al. The N-terminal and central domain of colicin A enables phage lysin to lyse Escherichia coli extracellularly. Antonie Leeuwenhoek. 2017;110:1627–1635. doi: 10.1007/s10482-017-0912-9. [DOI] [PubMed] [Google Scholar]
- 29.Huang C., Virk S.M., Shi J., Zhou Y., Willias S.P., Morsy M.K., Abdelnabby H.E., Liu J., Wang X., Li J. Isolation, Characterization and Application of Bacteriophage LPSE1 Against Salmonella enterica in Ready to Eat (RTE) Foods. Front. Microbiol. 2018;9 doi: 10.3389/fmicb.2018.01046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Mikoulinskaia G.V., Odinokova I.V., Zimin A., Lysanskaya V.Y., Feofanov S.A., Stepnaya O.A. Identification and characterization of the metal ion-dependent l-alanoyl-d-glutamate peptidase encoded by bacteriophage T5. FEBS J. 2009;276:7329–7342. doi: 10.1111/j.1742-4658.2009.07443.x. [DOI] [PubMed] [Google Scholar]
- 31.Briers Y., Walmagh M., Lavigne R. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J. Appl. Microbiol. 2011;110:778–785. doi: 10.1111/j.1365-2672.2010.04931.x. [DOI] [PubMed] [Google Scholar]
- 32.Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., Bairoch A. Protein Identification and Analysis Tools on the ExPASy Server. In: John M.W., editor. The Proteomics Protocols Handbook. Humana Press; Totowa, NJ, USA: 2005. pp. 571–607. [Google Scholar]
- 33.Lu S., Wang J., Chitsaz F., Derbyshire M.K., Geer R.C., Gonzales N.R., Gwadz M., I Hurwitz D., Marchler G.H., Song J.S., et al. CDD/SPARCLE: The conserved domain database in 2020. Nucleic Acids Res. 2020;48:D265–D268. doi: 10.1093/nar/gkz991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Sara E.-G., Jaina M., Alex B., Aurélien L., Matloob Q. The Pfam protein families database in 2019. Nucleic Acids Res. 2018;47:D427–D432. doi: 10.1093/nar/gky995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Drozdetskiy A., Cole C., Procter J.B., Barton G.J. JPred4: A protein secondary structure prediction server. Nucleic Acids Res. 2015;43:W389–W394. doi: 10.1093/nar/gkv332. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Schwede T., Kopp J., Guex N., Peitsch M.C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 2003;31:3381–3385. doi: 10.1093/nar/gkg520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Eisenberg D., Lüthy R., Bowie J.U. VERIFY3D: Assessment of protein models with three-dimensional profiles. Nature. 1992;356:83–85. doi: 10.1038/356083a0. [DOI] [PubMed] [Google Scholar]
- 38.Legotsky S.A., Vlasova K.Y., Priyma A.D., Shneider M.M., Pugachev V.G., Totmenina O.D., Kabanov A.V., Miroshnikov K., Klyachko N.L. Peptidoglycan degrading activity of the broad-range Salmonella bacteriophage S-394 recombinant endolysin. Biochimie. 2014;107:293–299. doi: 10.1016/j.biochi.2014.09.017. [DOI] [PubMed] [Google Scholar]
- 39.Li M., Li M., Lin H., Wang J., Jin Y., Han F. Characterization of the novel T4-like Salmonella Enterica bacteriophage STP4-a and its endolysin. Arch. Virol. 2015;161:377–384. doi: 10.1007/s00705-015-2647-0. [DOI] [PubMed] [Google Scholar]
- 40.Lim J.-A., Shin H., Kang D.-H., Ryu S. Characterization of endolysin from a Salmonella Typhimurium-infecting bacteriophage SPN1S. Res. Microbiol. 2012;163:233–241. doi: 10.1016/j.resmic.2012.01.002. [DOI] [PubMed] [Google Scholar]
- 41.Guo M., Feng C., Ren J., Zhuang X., Zhang Y., Zhu Y., Dong K., He P., Guo X., Qin J. A Novel Antimicrobial Endolysin, LysPA26, against Pseudomonas aeruginosa. Front. Microbiol. 2017;8:261. doi: 10.3389/fmicb.2017.00293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Geng P., Hu Y., Zhou G., Yuan Z., Hu X. Characterization of three autolysins with activity against cereulide-producing Bacillus isolates in food matrices. Int. J. Food Microbiol. 2017;241:291–297. doi: 10.1016/j.ijfoodmicro.2016.10.030. [DOI] [PubMed] [Google Scholar]
- 43.Oliveira H., Thiagarajan V., Walmagh M., Cerqueira M.A., Lavigne R., Neves-Petersen M.T., Kluskens L., Azeredo J. A Thermostable Salmonella Phage Endolysin, Lys68, with Broad Bactericidal Properties against Gram-Negative Pathogens in Presence of Weak Acids. PLoS ONE. 2014;9:e108376. doi: 10.1371/journal.pone.0108376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Schmelcher M., Powell A.M., Camp M.J., Pohl C.S., Donovan D.M. Synergistic streptococcal phage lambdaSA2 and B30 endolysins kill Streptococci in cow milk and in a mouse model of mastitis. Appl. Microbiol. Biotechnol. 2015;99:8475–8486. doi: 10.1007/s00253-015-6579-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Jumpei F., Tomohiro N., Takaaki F., Hazuki O., Hiromichi T., Junya K., Masaru U., Hidetoshi H., Yasunori T., Pharmaceuticals T.Y.J. Characterization of the Lytic Capability of a LysK-Like Endolysin, Lys-phiSA012, Derived from a Polyvalent Staphylococcus aureus Bacteriophage. Pharmaceuticals. 2018;11:25. doi: 10.3390/ph11010025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Son B., Yun J., Lim J.-A., Shin H., Heu S., Ryu S. Characterization of LysB4, an endolysin from the Bacillus cereus-infecting bacteriophage B4. BMC Microbiol. 2012;12:33. doi: 10.1186/1471-2180-12-33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Joshi H., Jain V. Novel method to rapidly and efficiently lyse Escherichia coli for the isolation of recombinant protein. Anal. Biochem. 2017;528:1–6. doi: 10.1016/j.ab.2017.04.009. [DOI] [PubMed] [Google Scholar]
- 48.Oliveira H., Pinto G., Oliveira A., Oliveira C., Faustino M.A., Briers Y., Domingues L., Azeredo J. Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates. Appl. Microbiol. Biotechnol. 2016;100:10543–10553. doi: 10.1007/s00253-016-7858-0. [DOI] [PubMed] [Google Scholar]
- 49.Wang Y., Sun J.H., Lu C. Purified Recombinant Phage Lysin LySMP: An Extensive Spectrum of Lytic Activity for Swine Streptococci. Curr. Microbiol. 2009;58:609–615. doi: 10.1007/s00284-009-9379-x. [DOI] [PubMed] [Google Scholar]
- 50.Pastagia M., Schuch R., Fischetti V.A., Huang D.B. Lysins: The arrival of pathogen-directed anti-infectives. J. Med Microbiol. 2013;62:1506–1516. doi: 10.1099/jmm.0.061028-0. [DOI] [PubMed] [Google Scholar]
- 51.Lu N., Sun Y., Wang Q., Qiu Y., Chen Z., Wen Y., Wang S., Song Y. Cloning and characterization of endolysin and holin from Streptomyces avermitilis bacteriophage phiSASD1 as potential novel antibiotic candidates. Int. J. Boil. Macromol. 2020;147:980–989. doi: 10.1016/j.ijbiomac.2019.10.065. [DOI] [PubMed] [Google Scholar]